A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors

Trial Profile

A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Mirvetuximab soravtansine (Primary)
  • Indications Adenocarcinoma; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors ImmunoGen
  • Most Recent Events

    • 06 Jun 2017 Results (n=113) of pooled analyses of three expansion cohorts assessing activity and safety presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 17 May 2017 Results of pooled analyses of three expansion cohorts from this trial published in an ImmunoGen Inc. media release.
    • 17 May 2017 Results from pooled analyses of three expansion cohorts from this trial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, according to an ImmunoGen Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top